Dietary inflammatory index and its relation to the pathophysiological aspects of obesity: a narrative review. 2023

Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
Universidade Federal de Goiás, Faculdade de Nutrição, Programa de Pós-graduação em Nutrição e Saúde, Goiânia, GO, Brasil.

Obesity, a complex disease that involves energy imbalance and chronic low-grade inflammation, is implicated in the pathogenesis of several chronic non-communicable diseases. As dietary components modulate the human body's inflammatory status, the Dietary Inflammatory Index (DII®), a literature-derived dietary index, was developed in 2009 to characterize the inflammatory potential of a habitual diet. Abundant research has been conducted to investigate the associations between DII and obesity. In this narrative review, we examined the current state of the science regarding the relationships between DII and the inflammatory pathophysiological aspects related to obesity. DII is associated with inflammation in obesity. The most pro-inflammatory diet was directly related to higher levels of pro-inflammatory markers, which included C-reactive protein (CRP), interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF-α). Therefore, evidence suggests that the use of the DII may be useful for understanding the relationship between diet and the inflammatory process related to obesity.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
August 2019, Nutrients,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
May 2021, Nutrients,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
January 2022, International journal of clinical practice,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
October 1976, Harefuah,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
July 2025, Nutrients,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
January 2023, Sao Paulo medical journal = Revista paulista de medicina,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
January 2022, International journal of clinical practice,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
January 2014, Hormone molecular biology and clinical investigation,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
July 2020, Journal of clinical medicine,
Roseli Neves de Mello, and Bárbara Paixão de Gois, and Ana Claudia Pelissari Kravchychyn, and Ana Raimunda Dâmaso, and Maria Aderuza Horst, and Glaucia Carielo Lima, and Flávia Campos Corgosinho
January 2024, Endocrine, metabolic & immune disorders drug targets,
Copied contents to your clipboard!